Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the benzothiazole class. It has been studied as an inhibitor of squalene-hopene cyclase (SHC), an isomerase enzyme involved in sterol and triterpene biosynthesis. The compound binds to the active site of SHC and inhibits its activity with reported IC50 values in the nanomolar range. It has primarily been used as a biochemical tool for structural studies of SHC and related enzymes but does not have any approved therapeutic indications or clinical development status as a pharmaceutical agent[5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-(6-{[3-(4-Bromophenyl)-1,2-Benzisothiazol-6-Yl]Oxy}Hexyl)-N-Methylprop-2-En-1-Amine.